a public good project by the
Synthesis
Company
of California

© 2026

M. Delage | doi.page

0 works0 citations0 h-index

M. Delage

Institut Pasteur(FR)Institut Pasteur(FR)Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer(FR)

Publications by Year

Research Areas

Hidradenitis Suppurativa and Treatments, Colorectal and Anal Carcinomas, Anorectal Disease Treatments and Outcomes, Autoimmune and Inflammatory Disorders, Microscopic Colitis

Most-Cited Works

→ Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project(2019)269 cited
→ The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study(2017)139 cited
→ Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients(2015)103 cited
→ The Surface Microbiome of Clinically Unaffected Skinfolds in Hidradenitis Suppurativa: A Cross-Sectional Culture-Based and 16S rRNA Gene Amplicon Sequencing Study in 60 Patients(2020)80 cited
→ Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa(2020)66 cited
→ Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa(2020)

62 cited

→ Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination(2014)49 cited

→ Efficacy of Infliximab for Hidradenitis Suppurativa: Assessment of Clinical and Biological Inflammatory Markers(2011)39 cited

→ Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients(2015)37 cited

→ Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients(2020)30 cited